bisindolylmaleimide i has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
bisindolylmaleimide I: a bis(indolyl)maleimide
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Le Naour, F | 1 |
| Francastel, C | 1 |
| Prenant, M | 1 |
| Lantz, O | 1 |
| Boucheix, C | 1 |
| Rubinstein, E | 1 |
1 other study available for bisindolylmaleimide i and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Upregulation of CD9 expression during TPA treatment of K562 cells.
Topics: Antigens, CD; Cell Differentiation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; | 1997 |